Table 3—

Comparison of the Cmax and Tmax in type 2 diabetic and nondiabetic subjects

Glucose (mmol/l) CmaxGlucose* (mmol/l) (Tmax)Insulin (mU/l) (Cmax)Insulin* (mU/l) (Tmax)C-peptide (pmol/l) (Cmax)C-peptide* (pmol/l) (Tmax)
Type 2 diabetic subjects
 Placebo11.1 (9.3–13.2)50.0 (30.0–75.0)73.8 (51.5–105.7)75.0 (30.0–120)2.1 (1.8–2.6)97.5 (75.0–120)
 Repaglinide10.0 (8.4–11.9)40.0 (30.0–90.0)108.6 (75.8–155.6)82.5 (50.0–120)3.2 (2.7–3.8)120 (75.0–120)
 Glipizide9.8 (8.2–11.7)50.0 (0.0–90.0)111.0 (77.4–59.0)82.5 (30.0–120)3.1 (2.5–3.7)105 (50.0–180)
 Glibenclamide10.3 (8.6–12.3)50.0 (30.0–75.0)111.4 (77.8–159.7)90.0 (40.0–120)3.0 (2.5–3.6)113 (60.0–240)
Nondiabetic subjects
 Placebo7.5 (6.9–8.2)30.0 (30.0–50.0)92.8 (73.4–117.4)50.0 (30.0–90.0)2.6 (2.2–3.0)55.0 (50.0–120)
 Repaglinide6.4 (5.9–7.0)30.0 (0.0–40.0)149.2 (118.0–188.7)50.0 (30.0–75.0)3.9 (3.3–4.6)60.0 (50.0–105)
 Glipizide6.7 (6.2–7.3)30.0 (20.0–40.0)158.5 (125.3–200.5)40.0 (30–120)3.6 (3.0–4.2)60.0 (50.0–120)
 Glibenclamide7.2 (6.6–7.8)40.0 (20.0–50.0)125.1 (98.9–158.2)55.0 (30.0–90.0)3.3 (2.8–3.9)75.0 (50.0–180)
  • Data are means (95% CI).

  • *

    * Median with minimum-maximum interval (brackets);

  • significant difference against placebo (P < 0.02);

  • significant difference against glibenclamide (P < 0.02).